Kardionitra s.r.o.

The department at Kardionitra s.r.o. is conducting studies aimed at primary prevention of atherosclerotic cardiovascular disease, evaluating a new therapy to lower the risk of major heart events.

• Evaluation of inclisiran for risk reduction
• Assessment of major adverse cardiovascular events (4P-MACE)
• Focus on high‑risk patients in primary prevention

These trials seek to demonstrate that the investigational treatment can significantly decrease cardiovascular death, heart attacks, strokes, and urgent revascularization procedures, offering a potential advance in preventive cardiology for the Slovak population.